STOCK TITAN

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Alignment Healthcare (ALHC) director reports an open‑market sale. Joseph S. Konowiecki sold 25,000 shares of common stock on 10/28/2025 at a price of $18 per share (transaction code S(1)). Following the sale, he beneficially owns 1,085,973 shares, held directly.

The footnote indicates a Rule 10b5‑1 trading plan adopted on 03/05/2025 in connection with the sale. No derivative securities transactions were reported in this filing.

Alignment Healthcare (ALHC) il direttore riferisce una vendita sul mercato aperto. Joseph S. Konowiecki ha venduto 25.000 azioni ordinarie il 28/10/2025 a un prezzo di 18 dollari per azione (codice di transazione S(1)). Dopo la vendita, detiene direttamente 1.085.973 azioni, beneficiando della titolarità.

La nota a piè di pagina indica un piano di negoziazione Rule 10b5-1 adottato il 03/05/2025 in relazione alla vendita. Nessuna operazione su strumenti derivati è stata riportata in questa presentazione.

Directora de Alignment Healthcare (ALHC) reporta una vendita sul mercato aperto. Joseph S. Konowiecki vendió 25,000 acciones comunes el 28/10/2025 a un precio de 18 dólares por acción (código de transacción S(1)). Tras la venta, posee beneficiosamente 1,085,973 acciones, mantenidas directamente.

La nota al pie indica un plan de negociación Rule 10b5-1 adoptado el 03/05/2025 en relación con la venta. No se reportaron transacciones de valores derivados en este archivo.

Alignment Healthcare(ALHC) 이사, 공개시장에서 매도 보고. Joseph S. Konowiecki는 2025년 10월 28일 주당 18달러에 보통주 25,000주를 매도했습니다 (거래 코드 S(1)). 매도 후 그는 직접 소유하는 1,085,973주를 보유합니다.

각주에 따르면 매매와 관련해 2025년 3월 5일에 채택된 Rule 10b5-1 매매 계획이 있습니다. 이 보고서에는 파생증권 거래가 보고되지 않았습니다.

Le directeur d'Alignment Healthcare (ALHC) signale une vente sur le marché libre. Joseph S. Konowiecki a vendu 25 000 actions ordinaires le 28/10/2025 à 18 dollars l'action (code de transaction S(1)). Après la vente, il détient directement 1 085 973 actions.

La note de bas de page indique un plan de négociation Rule 10b5‑1 adopté le 05/03/2025 dans le cadre de la vente. Aucune transaction sur des valeurs dérivées n'a été signalée dans ce dossier.

Alignment Healthcare (ALHC) Direktor meldet einen Handel am freien Markt. Joseph S. Konowiecki hat am 28.10.2025 25.000 Stammaktien zu 18 USD pro Aktie verkauft (Transaktionscode S(1)). Nach dem Verkauf besitzt er direkt 1.085.973 Aktien.

Die Fußnote gibt an, dass ein Rule 10b5‑1-Handelsplan am 05.03.2025 im Zusammenhang mit dem Verkauf eingeführt wurde. In dieser Einreichung wurden keine Derivate-Transaktionen berichtet.

مُدير Alignment Healthcare (ALHC) يُبلغ عن بيع في السوق المفتوح. باع جوزيف س. كونوفيتسكي 25,000 سهماً من الأسهم العادية في 28/10/2025 بسعر 18 دولاراً للسهم (رمز الصفقة S(1)). عقب البيع، يمتلك بشكل مستفيد 1,085,973 سهماً، مملوكة مباشرةً.

تشير الحاشية إلى خطة تداول من فئة Rule 10b5‑1 اعتمدت في 03/05/2025 فيما يتعلق بالبيع. لم تُبلغ أي معاملات على أدوات مشتقة في هذا الملف.

Positive
  • None.
Negative
  • None.

Alignment Healthcare (ALHC) il direttore riferisce una vendita sul mercato aperto. Joseph S. Konowiecki ha venduto 25.000 azioni ordinarie il 28/10/2025 a un prezzo di 18 dollari per azione (codice di transazione S(1)). Dopo la vendita, detiene direttamente 1.085.973 azioni, beneficiando della titolarità.

La nota a piè di pagina indica un piano di negoziazione Rule 10b5-1 adottato il 03/05/2025 in relazione alla vendita. Nessuna operazione su strumenti derivati è stata riportata in questa presentazione.

Directora de Alignment Healthcare (ALHC) reporta una vendita sul mercato aperto. Joseph S. Konowiecki vendió 25,000 acciones comunes el 28/10/2025 a un precio de 18 dólares por acción (código de transacción S(1)). Tras la venta, posee beneficiosamente 1,085,973 acciones, mantenidas directamente.

La nota al pie indica un plan de negociación Rule 10b5-1 adoptado el 03/05/2025 en relación con la venta. No se reportaron transacciones de valores derivados en este archivo.

Alignment Healthcare(ALHC) 이사, 공개시장에서 매도 보고. Joseph S. Konowiecki는 2025년 10월 28일 주당 18달러에 보통주 25,000주를 매도했습니다 (거래 코드 S(1)). 매도 후 그는 직접 소유하는 1,085,973주를 보유합니다.

각주에 따르면 매매와 관련해 2025년 3월 5일에 채택된 Rule 10b5-1 매매 계획이 있습니다. 이 보고서에는 파생증권 거래가 보고되지 않았습니다.

Le directeur d'Alignment Healthcare (ALHC) signale une vente sur le marché libre. Joseph S. Konowiecki a vendu 25 000 actions ordinaires le 28/10/2025 à 18 dollars l'action (code de transaction S(1)). Après la vente, il détient directement 1 085 973 actions.

La note de bas de page indique un plan de négociation Rule 10b5‑1 adopté le 05/03/2025 dans le cadre de la vente. Aucune transaction sur des valeurs dérivées n'a été signalée dans ce dossier.

Alignment Healthcare (ALHC) Direktor meldet einen Handel am freien Markt. Joseph S. Konowiecki hat am 28.10.2025 25.000 Stammaktien zu 18 USD pro Aktie verkauft (Transaktionscode S(1)). Nach dem Verkauf besitzt er direkt 1.085.973 Aktien.

Die Fußnote gibt an, dass ein Rule 10b5‑1-Handelsplan am 05.03.2025 im Zusammenhang mit dem Verkauf eingeführt wurde. In dieser Einreichung wurden keine Derivate-Transaktionen berichtet.

مُدير Alignment Healthcare (ALHC) يُبلغ عن بيع في السوق المفتوح. باع جوزيف س. كونوفيتسكي 25,000 سهماً من الأسهم العادية في 28/10/2025 بسعر 18 دولاراً للسهم (رمز الصفقة S(1)). عقب البيع، يمتلك بشكل مستفيد 1,085,973 سهماً، مملوكة مباشرةً.

تشير الحاشية إلى خطة تداول من فئة Rule 10b5‑1 اعتمدت في 03/05/2025 فيما يتعلق بالبيع. لم تُبلغ أي معاملات على أدوات مشتقة في هذا الملف.

Alignment Healthcare (ALHC) 董事报告公开市场销售。 Joseph S. Konowiecki 于 2025/10/28 以每股 18 美元的价格卖出 25,000 股普通股(交易代码 S(1))。出售后,他直接持有 1,085,973 股。

脚注表明,在此次出售相关的 Rule 10b5‑1 交易计划于 2025年03月05日被采纳。本文件未报告任何衍生证券交易。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KONOWIECKI JOSEPH S

(Last) (First) (Middle)
1100 W. TOWN & COUNTRY RD.
SUITE 1600

(Street)
ORANGE CA 92868

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/28/2025 S(1) 25,000 D $18 1,085,973 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Date of Rule 10b5-1 plan adoption: 03/05/2025
Remarks:
/s/ Christopher J. Joyce, as Attorney-in-Fact, for Joseph S. Konowiecki 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Alignment Healthcare, Inc.

NASDAQ:ALHC

ALHC Rankings

ALHC Latest News

ALHC Latest SEC Filings

ALHC Stock Data

3.39B
165.46M
3.91%
96.87%
6.09%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
ORANGE